In this article, we will look at the 10 Stocks to Buy on a Pullback.
Pullbacks tend to create favorable setups when they hit more than just the weakest parts of the market. In a broad selloff, fundamentally solid companies can get dragged lower alongside the rest of the market. That is what makes these periods worth watching. The opportunity is not in buying anything that is down, but in spotting stocks where the price has fallen faster than the underlying business has changed. After a long stretch when momentum and multiple expansion did much of the work, investors are once again paying closer attention to entry points and whether market weakness is creating a better risk-reward setup in companies that still look fundamentally intact.
That is also the message coming through in the institutional commentary. J.P. Morgan Asset Management says “High quality stocks are now priced at a discount,” adding that within U.S. markets, the quality factor is “more attractive than ever” outside unusually dislocated periods. Fidelity makes a similar point, saying “Market pullbacks can provide windows of opportunity” to buy quality stocks at “temporarily marked-down prices.” Putnam adds a useful market-level note that while the S&P 500 is “more expensive than average,” “many in this cohort are trading in line with or cheaper than their historical averages.” In other words, the broader market may still not look cheap, but individual opportunities are starting to emerge beneath the surface.
That is why stocks caught in a wider market pullback deserve a closer look, especially when the business still appears healthy, and the selloff looks more sentiment-driven than fundamental. With that in mind, let’s take a look at the 10 Stocks to Buy on a Pullback.
Our Methodology
We used the Finviz screener to identify stocks with an oversold RSI reading, forecasted annual EPS growth of at least 20% over the next 5 years, and viewed favorably by analysts. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Phillips 66 (NYSE:PSX)
On April 20, 2026, Phillips 66 (NYSE:PSX) and Kinder Morgan announced progress on the Western Gateway Pipeline after a successful second open season secured sufficient long-term shipper commitments to advance the project, pending final agreements and board approvals. The proposed system will link Midwest and Gulf Coast refinery supply to Phoenix, Arizona, and California markets, with additional connectivity to Las Vegas via Kinder Morgan’s CALNEV Pipeline. The project includes a new pipeline from Borger, Texas, to Phoenix, along with the reversal of Kinder Morgan’s existing SFPP pipeline to enable east-to-west product flows into California. The Gold Pipeline, currently running from Borger to St. Louis, will also be reversed to support supply into the system. The project is targeting an in-service date of mid-2029.
Earlier in April, Piper Sandler raised its price target on Phillips 66 to $177 from $168 while maintaining a Neutral rating, reflecting updated estimates based on recent trading trends, commodity pricing, and operating assumptions. The firm continues to see earnings tailwinds into 2026 and remains constructive on the broader refining outlook.
Similarly, Barclays raised its price target on Phillips 66 to $177 from $158 and kept an Equal Weight rating, citing benefits from commodity price tailwinds and what it views as a structurally higher valuation for the company’s energy infrastructure assets.
Phillips 66 (NYSE:PSX) operates as a diversified downstream energy company with refining, midstream, and marketing operations globally.
9. Takeda Pharmaceutical Company Limited (NYSE:TAK)
On April 8, 2026, Bernstein upgraded Takeda Pharmaceutical Company Limited (NYSE:TAK) to Outperform from Market Perform and raised its price target to ¥6,900 from ¥5,100, citing “bold” cost-cutting measures and a series of upcoming pipeline catalysts that could help de-risk the business.
On April 5, 2026, Denali Therapeutics announced that Takeda had decided to terminate their collaboration to co-develop and commercialize DNL593, an investigational progranulin replacement therapy for frontotemporal dementia. The decision was based on strategic considerations rather than safety or efficacy concerns, with Denali regaining full control of the program and its intellectual property.
Earlier, Axsome Therapeutics entered into an agreement with Takeda to acquire exclusive global rights to TAK-063, a selective phosphodiesterase 10A inhibitor. The asset will be developed for schizophrenia and Tourette syndrome, with Phase 3-enabling activities expected to begin in 2026. Under the deal, Takeda received an upfront payment and remains eligible for milestone payments and royalties tied to future development and commercialization.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company focused on developing and commercializing treatments across multiple therapeutic areas.
8. Occidental Petroleum Corporation (NYSE:OXY)
On April 12, 2026, UBS raised its price target on Occidental Petroleum Corporation (NYSE:OXY) to $67 from $64 while maintaining a Neutral rating. The firm noted ongoing exposure to the Middle East, including suspended operations at Al Hosn, but expects another strong operational update outside of that impact.
On April 8, 2026, Occidental Petroleum Corporation announced an oil discovery at the Bandit prospect in the Gulf of America, approximately 125 miles south of Louisiana. The well, located in Green Canyon Block 680, encountered high-quality oil-bearing Miocene sands. Occidental, which operates the project with a 45.375% working interest alongside Chevron and Woodside Energy, is evaluating results, with the discovery offering potential for subsea tie-backs to nearby infrastructure.
Earlier, Wells Fargo raised its price target on Occidental Petroleum Corporation to $72 from $69 and maintained an Overweight rating, adjusting its long-term oil price outlook to $75 Brent and $70 WTI following a ceasefire in Iran. The firm said the current setup resembles a mid-cycle correction that could present an entry point for a more orderly re-rating of select energy stocks.
Occidental Petroleum Corporation is an oil and gas exploration and production company with operations in the U.S. and internationally.
7. EQT Corporation (NYSE:EQT)
On April 14, 2026, Roth Capital analyst Leo Mariani maintained a Neutral rating on EQT Corporation (NYSE:EQT) with a $57 price target, noting that the company reported a $304M derivatives loss tied to hedging in Q1, which came in about $184M worse than the firm had expected. Earlier, TPH&Co. downgraded EQT to Hold from Buy with a $71 price target.
On March 27, 2026, BMO Capital raised its price target on EQT Corporation to $76 from $68 and kept an Outperform rating, pointing to strong operational execution that could drive outsized free cash flow. The firm highlighted the company’s integrated midstream and marketing capabilities, which allow it to capture pricing dislocations, along with continued momentum in in-basin demand and takeaway capacity supporting growth optionality.
Also in March, Truist initiated coverage of EQT Corporation with a Buy rating and a $74 price target, describing the company as the largest pure-play Appalachian natural gas producer with core assets across Pennsylvania, West Virginia, and Ohio. The firm believes EQT is well-positioned to benefit from an improving natural gas environment.
EQT Corporation explores, produces, and transports natural gas in the United States.
6. TKO Group Holdings, Inc. (NYSE:TKO)
On April 9, 2026, TKO Group Holdings, Inc. (NYSE:TKO) announced a multiyear sponsorship agreement with Supersure, making it the Official Small Business Insurance & Commercial Brokerage Technology Partner across UFC, Zuffa Boxing, and UFC BJJ events in the United States. The deal integrates Supersure into multiple properties, expanding its visibility across highly engaged sports audiences and marking the first time TKO has opened this sponsorship category.
TKO Group Holdings, Inc. also announced a separate multiyear partnership with FRE Nicotine Pouches, creating a broad collaboration across six properties, including UFC, Zuffa Boxing, PBR, UFC BJJ, and IMG-owned World’s Strongest Man and Formula Drift. Under the agreement, FRE becomes the Official Nicotine Pouch Partner, with plans for custom integrations and fan engagement initiatives targeting adult audiences.
Last month, Citizens initiated coverage of TKO Group Holdings, Inc. with an Outperform rating and a $240 price target, pointing to ongoing shifts in the media and entertainment landscape as streaming and personalization trends accelerate alongside advances in AI.
TKO Group Holdings, Inc. operates a portfolio of sports and entertainment brands, including UFC, WWE, and IMG.
5. GFL Environmental Inc. (NYSE:GFL)
On April 16, 2026, Stifel analyst Shlomo Rosenbaum lowered the price target on GFL Environmental Inc. (NYSE:GFL) to C$65 from C$84 while maintaining a Buy rating on the shares. The firm said the company’s investment narrative is shifting following its acquisition of Secure Waste Infrastructure and expects the stock to trade at an EV/EBITDA discount relative to solid waste peers.
On April 14, 2026, Citi also reduced its price target on GFL Environmental Inc. to $51 from $55 previously but kept a Buy rating, describing the Secure Waste deal as mixed overall. The firm added that the stock appears oversold.
Earlier in April, GFL Environmental Inc. announced it would acquire Secure Waste Infrastructure in a transaction valued at approximately C$6.4B, including debt, to expand its footprint in Western Canada. Under the terms, GFL will purchase all outstanding shares of Secure Waste for C$24.75 per share, funded through a mix of 20% cash and 80% stock.
GFL Environmental Inc. provides non-hazardous solid waste management services across Canada and the United States.
4. Antero Resources Corporation (NYSE:AR)
On April 20, 2026, Siebert Williams analyst Gabriele Sorbara raised the price target on Antero Resources Corporation (NYSE:AR) to $56 from $50 previously and maintained a Buy rating on the shares.
On April 16, 2026, Morgan Stanley also lifted its price target to $56 from $54 and kept an Overweight rating ahead of Q1 results. The firm expects most exploration and production companies to hold activity levels steady despite stronger oil prices, noting that while the sector has given back its March gains, energy prices are unlikely to return to pre-conflict levels in the near term.
Earlier in the month, Jefferies raised its price target on Antero Resources to $54 from $50 and maintained a Buy rating, estimating Q1 free cash flow of about $434M, supported by strong commodity realizations.
Meanwhile, BMO Capital raised its price target to $50 from $40 while keeping a Market Perform rating, incorporating updated Q1 mark-to-market assumptions. The firm noted that Winter Storm Fern has supported near-term free cash flow, while geopolitical tensions have improved the outlook for LPG pricing. BMO also highlighted potential incremental gas demand tied to large-scale data center developments in West Virginia.
Antero Resources Corporation explores and produces natural gas, NGLs, and oil in the United States.
3. Transocean Ltd. (NYSE:RIG)
On April 15, 2026, Transocean Ltd. (NYSE:RIG) announced that its Deepwater Asgard secured a five-well contract in the Eastern Mediterranean with an undisclosed operator. The campaign is expected to run for about 390 days, starting in Q4, and add approximately $158M to backlog, excluding additional services and mobilization-related fees. Including recent awards for the Transocean Barents in Norway and the Deepwater Orion, Deepwater Aquila, and Deepwater Corcovado in Brazil, total backlog additions since the start of April are estimated at around $1.6B.
On April 14, 2026, Morgan Stanley raised its price target on Transocean to $7 from $5 while maintaining an Equal Weight rating. The firm said higher oil prices, beyond ongoing Middle East disruptions, could support increased upstream spending, adding that its 2027–2028 EBITDA estimates are now roughly 6% above consensus across its energy services coverage.
Earlier in the month, Transocean announced a series of contract awards and extensions totaling about $1.0B in incremental backlog. These include a 1,095-day contract for the Transocean Barents with Var Energi in Norway at a day rate of $450,000, expected to begin in mid-2027 and contribute roughly $490M. The contract also includes options that could extend operations through 2034. In Brazil, the Deepwater Orion received a 1,095-day extension with Petrobras worth about $420M, keeping the rig contracted through March 2030, while the Deepwater Aquila secured a 365-day extension valued at approximately $160M, extending its commitment through June 2028.
Transocean Ltd. provides offshore drilling services for oil and gas exploration and development worldwide.
2. Comstock Resources, Inc. (NYSE:CRK)
On April 15, 2026, Citi analyst Scott Gruber lowered the price target on Comstock Resources, Inc. (NYSE:CRK) to $19 from $24 previously and maintained a Neutral rating on the shares. The firm updated its model ahead of earnings, projecting a discretionary cash flow of about $230.1M, slightly below the roughly $244.8M consensus, primarily due to more conservative commodity price assumptions. Citi also expects production to come in around the midpoint of guidance, with a modest sequential increase.
Last month, Comstock Resources, Inc. announced that its Western Haynesville operations will support the newly designated Texas Natural Gas-Fired Power Generation Hub in Anderson County, Texas. The project was selected by the U.S. Department of Commerce as part of Japan’s $550B investment commitment tied to the U.S.-Japan trade agreement. The development is a collaboration between Comstock and NextEra Energy (NYSE:NEE), which will build and operate the facility. The project is expected to deliver up to 5.2 GW of natural gas-fired capacity, capable of supporting roughly 5 GW of large-scale demand. Comstock is positioned to supply natural gas to the facility, with volumes potentially approaching 1 Bcf per day by 2031. The total project cost is estimated at $16B and remains subject to final agreements and development milestones.
Comstock Resources, Inc. explores, develops, and produces natural gas and oil assets in the United States.
1. AbbVie Inc. (NYSE:ABBV)
On April 20, 2026, Canaccord initiated coverage of AbbVie Inc. (NYSE:ABBV) with a Buy rating and a $262 price target on the shares, offering an upside potential of around 29% from AbbVie Inc.’s last close.
On April 12, 2026, CollPlant disclosed that Allergan Industrie SAS, an AbbVie company, exercised its right to terminate a development agreement originally signed in February 2021, with termination taking effect after a 60-day notice period. The partnership had focused on developing dermal and soft tissue fillers using CollPlant’s rhCollagen technology for the medical aesthetics market. Despite the termination, CollPlant indicated it continues to see strong interest in its collagen platform and is actively pursuing new partnerships, including discussions with multiple strategic and Tier 1 companies for potential collaborations in aesthetic applications.
A day earlier, AbbVie Inc. announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented at the 2026 Society of Gynecologic Oncology Annual Meeting. The study evaluated mirvetuximab soravtansine-gynx (Elahere) in combination with carboplatin, followed by monotherapy maintenance, in patients with folate receptor alpha-positive, platinum-sensitive ovarian cancer. The trial enrolled 125 patients and focused on objective response rate as the primary endpoint, with additional measures including duration of response, progression-free survival, and overall survival.
AbbVie Inc. develops and markets pharmaceutical therapies across multiple therapeutic areas globally.
READ NEXT: 10 Best Stocks That Beat Earnings Estimates and 10 Best 52-Week Low NASDAQ Stocks to Buy Now.
